Alnylam Pharmaceuticals, Inc.
(NASDAQ : ALNY)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 10.73%61.500.0%$1907.60m
REGNRegeneron Pharmaceuticals, Inc. 5.98%612.812.5%$1175.40m
GILDGilead Sciences, Inc. 3.33%77.831.0%$1168.63m
AMGNAmgen, Inc. 2.49%229.701.3%$672.54m
VRTXVertex Pharmaceuticals, Inc. 3.81%287.961.9%$606.67m
NVAXNovavax, Inc. 2.68%46.04102.0%$590.02m
BIIBBiogen, Inc. 2.19%307.091.6%$417.42m
ILMNIllumina, Inc. -2.67%363.053.5%$387.48m
SRNESorrento Therapeutics, Inc. 2.02%5.051.8%$306.68m
ALXNAlexion Pharmaceuticals, Inc. 4.79%119.902.0%$292.13m
SGENSeattle Genetics, Inc. 3.74%157.216.1%$269.08m
AAgilent Technologies, Inc. 1.67%88.141.6%$202.48m
BMRNBioMarin Pharmaceutical, Inc. 0.90%106.554.3%$186.35m
CODXCo-Diagnostics, Inc. 3.03%18.000.0%$173.36m
INCYIncyte Corp. 1.35%101.912.5%$166.15m

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.